Business
Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies
Niowave Inc., a U.S.-based global leader in medical radioisotope production, today announced a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides Novartis with a scalable supply of this critical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells. Financial terms of the agreement are not being disclosed.
About this update from Novartis Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising medical isotope","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"The long-term supply agreement supports the development of next-generation therapies designed to precisely target and eliminate cancer cells","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"LANSING, Mich., Feb. 11, 2026 /PRNewswire/ -- Niowave Inc., a U.S.-based global leader in medical radioisotope production, today announced a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides Novartis with a scalable supply of this critical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells. Financial terms of the agreement are not being disclosed.","length":521,"tagName":"p"},{"type":"image","alt":"Niowave Logo (PRNewsfoto/Niowave Inc.)","displaySize":"","headline":null,"caption":"Niowave Logo (PRNewsfoto/Niowave Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":106,"url":"https://media.zenfs.com/en/prnewswire.com/cbef55f737889ef366749a34e9fbaf03"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XgtOinkFv1XQzPqZqLoeig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cbef55f737889ef366749a34e9fbaf03","width":400,"height":106}},"href":"https://mma.prnewswire.com/media/2849105/Niowave_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The long-term agreement supports Novartis's growing portfolio of RLT programs for difficult-to-treat cancers. In turn, Niowave expects to expand production capacity, and to support that growth, intends to begin construction of a new manufacturing facility in Lansing, Michigan, in early 2026.","length":296,"tagName":"p"},{"type":"text","content":""Our new agreement with Novartis underscores Niowave's leading position as a trusted global supplier of medical radioisotopes," said Mike Zamiara, Chief Executive Officer of Niowave. "Niowave's ability to provide dependable, scalable supply of Actinium-225 will contribute to the advancemen...